Álcool e nicotina
mecanismos de dependência
DOI:
https://doi.org/10.34024/rnc.2010.v18.8436Palavras-chave:
Etanol, Nicotina, DependênciaResumo
O trabalho trata dos mecanismos envolvidos na dependência ao álcool e à nicotina. A dependência é caracterizada pelo uso compulsivo de uma determinada substância, que leva a uma inabilidade em limitar o consumo e ao surgimento de uma síndrome de abstinência durante a interrupção. O reforço ou recompensa ocorre quando neurônios liberam dopamina para o nucleus accumbens após o consumo da droga. A tolerância consiste na diminuição de sensibilidade ao efeito da droga de tal modo que, com o passar do tempo, doses maiores são necessárias para a obtenção do mesmo efeito. Várias drogas que podem atuar bloqueando os mecanismos de dependência são utilizadas ou estão sendo desenvolvidas para o tratamento da dependência a essas drogas.
Downloads
Métricas
Referências
King AC, Epstein AM. Alcohol dose-dependent increases in smoking urge in light smokers. Alcohol Clin Exp Res. 2005;29:547-52.
Vasconcelos SMM, Macêdo DS, Lima LO, Sousa FCF, Fonteles MMF, Viana GSB. Effects of one-week ethanol treatment on monoamine levels and dopamine receptors in rat striatum. Braz J Med Biol Res. 2003;36:503-9.
Vasconcelos SMM, Cavalcante RA, Aguiar LMV, Sousa FCF, Fonteles MMF, Viana GSB. Effects of chronic ethanol treatment on monoamine levels in rat hippocampus and striatum. Braz J Med Biol Res. 2004;37:1839-46.
Cunha GH, Jorge ARC, Fonteles MMF, Sousa FCF, Viana GSB, Vasconcelos SMM. Nicotina e tabagismo. Rev Elet Pes Méd 2007;1:1-10.
Wong DVT, Ferreira JRO, Fonteles MMF, Viana GSB, Sousa FCF, Vasconcelos SMM. Álcool e Neurodesenvolvimento: Aspectos Genéticos e Farmacológicos. Revista Eletrônica da Faculdade de Farmácia. 2008;1:16-31.
Bustamante D, Quintanilla ME, Tampier L, Gonzalez-Lira V, Israel Y, Herrera-Marschitz M. Ethanol induces stronger dopamine release in nucleus accumbens (shell) of alcohol-preferring (bibulous) than in alcoholavoiding (abstainer) rats. Eur J Pharmacol 2008;591:153-8.
Lyness WH, Smith FL. Influence of dopaminergic and serotonergic neurons on intravenous ethanol self-administration in the rat. Pharmacol Biochem Behav 1992;42:187-92.
Funk D, Marinelli PW, Lê AD. Biological processes underlying co-use of alcohol and nicotine: neuronal mechanisms, cross-tolerance, and genetic factors. Alcohol Res Health 2006;29:186-92.
Gupta S, Kulhara P. Cellular and molecular mechanisms of drug dependence: An overview and update. Indian J Psychiatry 2007;49:85-90.
Wise RA. Addiction becomes a brain disease. Neuron. 2000;26:27-33.
White FJ. A Behavioral/Systems Approach to the Neuroscience of Drug Addiction. J Neurosci 2002;22:3303-5.
Balfour DJ. The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus. Nicotine Tob Res 2004;6:899-912.
Benowitz NL. Nicotine addiction. Prim Care 1999;26:611-31.
Mansvelder HD, Mc Gehee DS. Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol 2002;53: 606–17.
Tobacco Addiction (endereço na internet). National Institute on Drug Abuse (NIDA). NIH Publication Number 06-4342. 2006. (atualizado em: 2005; acessado em: 12/2009). Disponível em: http://www.nida.nih.gov/PDF/RRTobacco.pdf
Rang HP, Dale MM, Ritter JM, Moore PK. Farmacologia. 6ª. ed. Elsevier, 2007, 920p.
Breitinger HGA, Geetha N, Hess GP. Inhibition of the serotonin 5-HT3 receptor by nicotine, cocaine, and fluoxetine investigated by rapid chemical kinetic techniques. Biochemistry 2001;40:8419-29.
Xu Z, Seidler FJ, Ali SF, Slikker W, Slotkin TA. Fetal and adolescent nicotine administration: effects on CNS serotoniergic systems. Brain Res. 2001;914:166-78.
Mansvelder HD, De Rover M, McGehee DS. Cholinergic modulation of dopaminergic reward areas: upstream and downstream targets of nicotine addiction. Eur J Pharmacol. 2003;480:117-23.
Benowitz NL. Neurobiology of Nicotine Addiction: Implications for Smoking Cessation Treatment. The American J Med 2008;121:S3-S10.
Brunton LB, Lazo JS, Parker KL. Goodman & Gilman Bases farmacológicas da terapêutica. 11ª. ed. McGraw-ill; 2005, 1821p.
Vaillant GE. A história natural do alcoolismo revisitada. São Paulo: Artes Médicas Sul, 1999, 185p.
Larini L, Salgado PET. Compostos voláteis. In: Larini L. Toxicologia. 2ª. ed. São Paulo: Manole, 1997, p.73-119.
Internações por problemas com drogas psicotrópicas no Brasil. O Álcool é ainda o Grande Vilão! (endereço na Internet). CEBRID - Centro Brasileiro de Informações sobre Drogas Psicotrópicas. Boletim, n. 41, junho 2000 (atualizado em: 2000; acessado em: 10/2009). Disponível em: http://www.unifesp.br/dpsicobio/boletim/ed41/14.htm
Gordis E. The neurobiology of alcohol abuse and alcoholism: building knowledge, creating hope. Drug Alcohol Depend 1998;51:9-11.
Koob GF, Roberts AJ, Schulteis G, Parsons LH, Heyser CJ, Hyytia P, et al. Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res 1998;22:3-9.
Grobin AC, Matthews DB, Devaud LL, Morrow AL. The role of GABAA receptors in the acute and chronic effects of ethanol. Psychopharmacol 1998;139:2-19.
Weiss F, Parsons LH, Schulteis G, Hyytia P, Lorang MT, Bloom FE, et al. Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats. J. Neurosci 1996;16:3474-85.
Bienkowski P, Kostowski W, Koros E. The role of drug-paired stimuli in extinction and reinstatement of ethanol-seeking behaviour in the rat. Eur J Pharmacol 1999;374:315-9.
Di Chiara G. Alcohol and dopamine. Alcohol World Health Res 1997;21:108-13.
Morzorati SL, Johnson TB. Serotonergic neuronal activity in the dorsal raphe nucleus of selectively bred alcohol-preferring and alcohol-nonpreferring rats and unselected wistar rats. Alcohol Clin Exp Res 1999;23:1362-7.
Berggren U, Eriksson M, Fahlke C, Balldin J. Relationship between central serotonergic neurotransmission and reduction in alcohol intake by citalopram. Drug Alcohol Depen 2001;63:262-7.33.Le Marquand D, Pihl RO, Benkelfat C. Serotonin and alcohol intake, abuse, and dependence: Clin Evid Biol Psychiatry 1994;36:326-37.
Lovinger DM. Alcohols and neurotransmitter gated ion channels: past, present and future. Naunyn Schmiedebergs Arch Pharmacol 1997;356:267-82.
Rossetti ZL, Longu G, Mercuro G, Hmaidan Y, Gessa GL. Biphasic effect of ethanol on noradrenaline release in the frontal cortex of awake rats. Alcohol Alcohol 1992;27:477-80.
Vasconcelos SMM, Sales GTM, Lima NM, Soares PM, Pereira EC, Fonteles MMF, et al. Determination of amino acid levels in the rat striatum, after administration of ethanol alone and associated with ketamine, a glutamatergic antagonist. Neurosci Letters 2008;444:48-51.
Gonzales RA, Jaworski JN. Alcohol and glutamate. Alcohol Health & Research World 1997;21:120-6.
Morrisetti RA, Swartzwelder HS. Attenuation of hippocampal longterm potentiation by ethanol: a patch-clamp analysis of glutamatergic and GABAergic mechanisms. J Neurosci 1993;13:2264-72.
Dodd PR, Beckmann AM, Davidson MS, Wilce PA. Glutamate-mediated transmission, alcohol, and alcoholism. Neurochemistry Internacional 2000;37:509-33.
Soderpalm B, Ericson M, Olausson P, Blomqvist O, Engel JA. Nicotinic mechanisms involved in the dopamine activating and reinforcing properties of ethanol. Behav Brain Res 2000;113:85-96.
Ikonomidou C, Bittigau P, Ishimaru MJ, Wozniak DF, Koch C, Genz K, et al. Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome. Science. 2000;287:1056-60.
Ryabinin AE. Role of hippocampus in alcohol-induced memory impairment: implication from behavorial and immediate early gene studies. Psychopharmacol 1998;139:34-43.
Hatsumaki DK, Stead LF, Gupta PC. Tobacco addiction. Lancet. 2008;371:2027–38.
Benowitz NL. Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics. Annu Rev Pharmacol Toxicol 2008; 49:57–71.
Steensland P, Simms J, Holgate J, Richards JK, Bartlett SE. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. PNAS 2007;104:12518-23.
Mayo-Smith ME. For the American Society of Addiction Medicine Working Group for Practice Guideline on Pharmacology Management of Alcool Withdrawal. Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. JAMA 1997;278:144-51.
Hoffman PL, Rabe CS, Grant KA, Valverius P, Hudspith M, Tabakoff B. Ethanol and the NMDA receptor. Alcohol 1990;7:229-31.
Riaz A, Faingold CL. Seizures during ethanol withdrawal are blocked by focal microinjection of excitant amino acid antagonists into the inferior colliculus and pontine reticular formation. Alcohol Clin Exp Res 1994;18:1456-62.
Weiss F, Mitchiner M, Bloom FE, Koob GF. Free-choice responding for ethanol versus water in alcohol preferring (P) and unselected Wistar rats is differentially modified by naloxone, bromocriptine, and methysergide. Psychopharmacol 1990;101:178-86.
Ng GY, George SR. Dopamine receptor agonist reduces ethanol selfadministration in the ethanol-preferring C57BL/6J inbred mouse. Eur J Pharmacol 1994;169:365-74.
Shaw GK, Majumdar SK, Waller S, Macgarvie J, Dunn G. Tiapride in the long-term management of alcoholics of anxious or depressive temperament. Br J Psychiatry 1987;150:164-8.
Shaw GK, Waller S, Majumdar SK, Alberts JL, Latham CJ, Dunn G. Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry 1994;165:515-23.
Benjamin D, Grant ER, Pohorecky LA. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res 1993;621:137-40.
Fiellin DA, Reid MC, O’Connor PG. Outpatient management of patients with alcohol problems. Ann Intern Med 2000;133:815-27.
Dahchour A, De Witte P. Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. Prog Neurobiol 2000;60:343-62.
Downloads
Publicado
Como Citar
Edição
Seção
Publicado: 2010-12-31
Português
English
Español
